Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.

Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, Huang M, Vlad AM, Lu B, Oesterreich S, Davidson NE, Huang Y.

Oncogene. 2018 Aug 15. doi: 10.1038/s41388-018-0451-5. [Epub ahead of print]

PMID:
30111819
2.

Inflammatory biomarker in adipose stem cells of women with endometrial cancer.

Linkov F, Goughnour SL, Adambekov S, Lokshin A, Kelley JL, Sukumvanich P, Comerci JT, Marra KG, Kokai LE, Rubin JP, Vlad AM, Philips BJ, Edwards RP.

Biomark Med. 2018 Sep;12(9):945-952. doi: 10.2217/bmm-2017-0355. Epub 2018 Jul 25.

PMID:
30043637
3.

Restraint and Social Isolation Stressors Differentially Regulate Adaptive Immunity and Tumor Angiogenesis in a Breast Cancer Mouse Model.

Budiu RA, Vlad AM, Nazario L, Bathula C, Cooper KL, Edmed J, Thaker PH, Urban J, Kalinski P, Lee AV, Elishaev EL, Conrads TP, Flint MS.

Cancer Clin Oncol. 2017 May;6(1):12-24. doi: 10.5539/cco.v6n1p12. Epub 2016 Nov 11.

4.

Summary of the 2016 American Association for Cancer Research (AACR) Annual Meeting.

Fuh K, Vlad AM, Landen CN Jr.

Gynecol Oncol. 2016 Jul;142(1):9-12. doi: 10.1016/j.ygyno.2016.05.013. Epub 2016 May 27. No abstract available.

PMID:
27181388
5.

Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.

Zhang L, Ma T, Brozick J, Babalola K, Budiu R, Tseng G, Vlad AM.

Oncogene. 2016 Sep 22;35(38):5010-20. doi: 10.1038/onc.2016.53. Epub 2016 Mar 14.

6.

Chronic inflammation in endometriosis and endometriosis-associated ovarian cancer: New roles for the "old" complement pathway.

Edwards RP, Huang X, Vlad AM.

Oncoimmunology. 2015 Feb 3;4(5):e1002732. eCollection 2015 May.

7.

Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.

Mony JT, Zhang L, Ma T, Grabosch S, Tirodkar TS, Brozick J, Tseng G, Elishaev E, Edwards RP, Huang X, Vlad AM.

Cancer Immunol Immunother. 2015 Sep;64(9):1095-108. doi: 10.1007/s00262-015-1712-6. Epub 2015 May 22.

8.

Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse model.

Ocak M, Gillman AG, Bresee J, Zhang L, Vlad AM, Müller C, Schibli R, Edwards WB, Anderson CJ, Gach HM.

Mol Pharm. 2015 Feb 2;12(2):542-53. doi: 10.1021/mp500628g. Epub 2015 Jan 14.

9.

Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer.

Suryawanshi S, Huang X, Elishaev E, Budiu RA, Zhang L, Kim S, Donnellan N, Mantia-Smaldone G, Ma T, Tseng G, Lee T, Mansuria S, Edwards RP, Vlad AM.

Clin Cancer Res. 2014 Dec 1;20(23):6163-74. doi: 10.1158/1078-0432.CCR-14-1338. Epub 2014 Oct 7.

10.

MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location.

Tirodkar TS, Budiu RA, Elishaev E, Zhang L, Mony JT, Brozick J, Edwards RP, Vlad AM.

PLoS One. 2014 Jul 31;9(7):e102409. doi: 10.1371/journal.pone.0102409. eCollection 2014.

11.

Plasma microRNAs in ovarian cancer--response.

Huang X, Vlad AM.

Clin Cancer Res. 2013 Jun 15;19(12):3326. doi: 10.1158/1078-0432.CCR-13-1022. Epub 2013 Apr 24. No abstract available.

12.

Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer.

Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards RP, Huang X.

Clin Cancer Res. 2013 Mar 1;19(5):1213-24. doi: 10.1158/1078-0432.CCR-12-2726. Epub 2013 Jan 29.

13.

Immunobiology of human mucin 1 in a preclinical ovarian tumor model.

Budiu RA, Elishaev E, Brozick J, Lee M, Edwards RP, Kalinski P, Vlad AM.

Oncogene. 2013 Aug 8;32(32):3664-75. doi: 10.1038/onc.2012.397. Epub 2012 Sep 10.

14.

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.

Mantia-Smaldone GM, Edwards RP, Vlad AM.

Cancer Manag Res. 2011;3:25-38. doi: 10.2147/CMR.S8759. Epub 2010 Dec 30.

15.

Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.

Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM.

Cancer Immunol Immunother. 2011 Jul;60(7):975-84. doi: 10.1007/s00262-011-1010-x. Epub 2011 Apr 2.

PMID:
21461842
16.

Restraint stress and stress hormones significantly impact T lymphocyte migration and function through specific alterations of the actin cytoskeleton.

Flint MS, Budiu RA, Teng PN, Sun M, Stolz DB, Lang M, Hood BL, Vlad AM, Conrads TP.

Brain Behav Immun. 2011 Aug;25(6):1187-96. doi: 10.1016/j.bbi.2011.03.009. Epub 2011 Mar 21.

PMID:
21426930
17.

A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells.

Budiu RA, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Vlad AM.

Dis Model Mech. 2009 Nov-Dec;2(11-12):593-603. doi: 10.1242/dmm.002535. Epub 2009 Oct 19.

18.

A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer.

Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, Crowley-Nowick PA, Kelley JL, Price FV, Edwards RP.

Cancer Immunol Immunother. 2010 Feb;59(2):293-301. doi: 10.1007/s00262-009-0750-3.

PMID:
19690855
19.

Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.

Ryan SO, Vlad AM, Islam K, Gariépy J, Finn OJ.

Biol Chem. 2009 Jul;390(7):611-8. doi: 10.1515/BC.2009.070.

20.

Von Recklinghausen's disease--elements of clinical practice.

Burnei G, Vlad C, Georgescu I, Gavriliu S, Dan D, Vlad AM.

Rom J Intern Med. 2006;44(4):377-87. Review.

PMID:
18386614

Supplemental Content

Support Center